Fischer Medical Ventures' Q2 FY 2025-26 Quarterly Results

Result Summary

• Fischer Medical Ventures Ltd reported a 187.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 122.6%.
• Its expenses for the quarter were up by 246.7% QoQ and 81.0% YoY.
• The net profit increased 177.4% QoQ and increased 4693.1% YoY.
• The earnings per share (EPS) of Fischer Medical Ventures Ltd stood at 2.11 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Fischer Medical Ventures Ltd is a company engaged in the healthcare sector, specializing in medical technology and related products. While detailed information about the company's specific products or recent developments is not available in the provided data, it is assumed to operate within the medical field, potentially offering a range of innovative healthcare solutions. The company's performance in the market is crucially influenced by advancements in medical technologies, regulatory changes, and overall healthcare demand.

Revenue

During the second quarter of FY26, Fischer Medical Ventures Ltd reported a total income of ₹88.79 crores. This represents a significant quarter-over-quarter (QoQ) increase of 187.3% from ₹30.91 crores in Q1FY26 and a year-over-year (YoY) increase of 122.6% from ₹39.88 crores in Q2FY25. The substantial rise in income indicates a robust growth trajectory over both the quarterly and yearly periods. A detailed examination of revenue streams and factors contributing to these increases would provide further insights into the company's financial health and strategic positioning.

Profitability

Profitability metrics for Fischer Medical Ventures Ltd display notable improvements in Q2FY26. The company achieved a profit before tax of ₹17.30 crores, marking a 70.1% QoQ increase from ₹10.17 crores in Q1FY26 and an extraordinary YoY increase of 4452.6% from ₹0.38 crores in Q2FY25. After accounting for tax expenses, the profit after tax stood at ₹13.90 crores, with a QoQ growth of 177.4% and a YoY growth of 4693.1%. The earnings per share also saw a substantial rise to ₹2.11, reflecting a 2244.4% QoQ increase and a 4120.0% YoY increase. These figures highlight significant profitability gains over the observed periods.

Operating Metrics

The financial performance of Fischer Medical Ventures Ltd in Q2FY26 also indicates increased operational efficiency. Total expenses for the quarter were ₹71.48 crores, which represents a 246.7% QoQ increase from ₹20.62 crores in Q1FY26 and an 81.0% YoY increase from ₹39.50 crores in Q2FY25. Despite the rise in expenses, the company's profit margins have improved, as evidenced by the substantial increases in profit before and after tax. The tax expense for Q2FY26 was ₹3.37 crores, which decreased by 34.8% QoQ from ₹5.17 crores in Q1FY26, while demonstrating a significant shift from a negative tax scenario in Q2FY25. These metrics reflect the company's ability to manage its operating costs effectively while maintaining profitability.